Answers are grounded in this paper and cite their sources.
Case report describes successful treatment of ulcerative colitis after mesalamine-induced myocarditis, suggesting new options for management.
Background Mesalamine intolerance occurs in 5–10% of patients with ulcerative colitis (UC), while myocarditis is an extremely rare but potentially fatal complication. Optimal UC management after mesalamine-induced myocarditis remains unclear. Case presentation A man in his 30s with left-sided UC developed mesalamine-induced myocarditis three weeks after treatment initiation, confirmed by elevated troponin-T, reduced ejection fraction (23%), and a positive drug-induced lymphocyte stimulation test. Cardiac function improved with corticosteroids; however, UC relapsed during steroid tapering. After multidisciplinary discussion and shared decision-making, upadacitinib was selected considering potential cardiac risk with anti-TNF therapy and the need to minimize corticosteroid exposure. Rapid clinical improvement was observed, and complete mucosal healing (Mayo endoscopic subscore 0) was confirmed at 6-month follow-up colonoscopy. Conclusion This is the first reported case of UC complicated by mesalamine-induced myocarditis successfully treated with upadacitinib. JAK inhibitors may represent a therapeutic option when conventional biologics are unsuitable in patients with severe mesalamine intolerance.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: